[A25-63] Tislelizumab (NSCLC, second line or later) – Addendum to Project A24-128
Last updated 18.06.2025
Project no.:
A25-63
Commission:
Commission awarded on 06.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior treatment with platinum-based chemotherapy; in addition, patients with epidermal growth factor receptor mutant or anaplastic lymphoma kinase positive NSCLC should also have received targeted therapies before receiving tislelizumab.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-63
| Project no. | Title | Status |
|---|---|---|
| A24-128 | Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
Federal Joint Committee (G-BA)
18.06.2025 A G-BA decision was published.
G-BA documents on this decision